~~<i id='85C69ADCCA'><strike id='85C69ADCCA'><tt id='85C69ADCCA'><pre id='85C69ADCCA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

comprehensive

author：knowledge 2025-10-02 22:15:24 - browse：275

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Listen: Wegovy in the brain & pivotal Alzheimer's data

hotspot

Wikipedia

explore

hotspot

focus

FABRICECOFFRINI/AFP/GettyImagesTheWorldHealthOrganizationannouncedMondaythatitwouldconveneanexpertpa

WSS

Steward Health Care Massachusetts hospitals face fiscal disaster

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

STAT Virtual Event: The State of Biosimilars: What to Watch

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Amid AI frenzy, a top HHS official's quest to create safeguards

RaDonda Vaught links Vanderbilt hospital issues to patient death

knowledge

comprehensive

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

HHS secretary Becerra pressed on Change HealthCare cyberattack

Hepatitis C has a cure — but many Americans still lack access to it

Steward Health Care Massachusetts hospitals face fiscal disaster

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Medicare details structure of new drug price negotiation program

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Wikipedia

Medicare coverage of Wegovy, once blocked, now looks possible

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

As digital health tech proliferates, a new institute aims to cut through hype

Steward Health Care Massachusetts hospitals face fiscal disaster

Boston's new lab space is opening empty

Startup Neumora takes a novel depression drug to Phase 3

Wikipedia

explore

hotspot

focus